Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down After Earnings Miss

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)’s share price gapped down prior to trading on Thursday following a dissappointing earnings announcement. The stock had previously closed at $108.62, but opened at $96.53. Mirum Pharmaceuticals shares last traded at $94.9690, with a volume of 253,699 shares traded.

The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The firm had revenue of $148.93 million during the quarter, compared to analysts’ expectations of $141.78 million. During the same quarter in the prior year, the firm posted $1.00 EPS. Mirum Pharmaceuticals’s quarterly revenue was up 49.8% compared to the same quarter last year.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Revenue beat and strong top-line growth: Q4 revenue was $148.93M vs. consensus $141.78M, up ~49.8% year-over-year — evidence of accelerating commercial traction. Business Wire: Q4 Results
• Neutral Sentiment: Earnings call details available — management provided a business update and commentary on execution and the outlook; read the call transcript for color on commercial drivers and any pipeline or margin comments. Fool: Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Market momentum and technicals are under discussion — sentiment pieces note strong upward momentum over the past year but warn technical indicators are stretched, which could amplify near-term volatility. Seeking Alpha: Technicals Article
• Negative Sentiment: EPS miss and ongoing GAAP loss: Q4 EPS of ($0.11) missed consensus $0.02, and the company remains unprofitable (negative net margin and ROE), which keeps profitability risk front-and-center for investors. Zacks: Q4 Loss, Revenue Beat
• Negative Sentiment: FY2026 revenue guidance of $630M–$650M is slightly below consensus (~$645.9M) and EPS guidance was not clearly raised in the release, leaving uncertainty on near-term profitability improvement. Business Wire: Guidance

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price objective on shares of Mirum Pharmaceuticals in a research note on Monday, December 8th. Raymond James Financial reiterated a “strong-buy” rating and set a $110.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. HC Wainwright upped their price objective on Mirum Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Finally, Stifel Nicolaus lifted their target price on Mirum Pharmaceuticals from $98.00 to $125.00 and gave the company a “buy” rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $111.75.

Insider Transactions at Mirum Pharmaceuticals

In other news, insider Joanne Quan sold 6,911 shares of the company’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $90.27, for a total transaction of $623,855.97. Following the completion of the transaction, the insider directly owned 11,305 shares of the company’s stock, valued at approximately $1,020,502.35. This represents a 37.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Peter Radovich sold 3,143 shares of the firm’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $96.19, for a total value of $302,325.17. Following the sale, the chief operating officer directly owned 23,286 shares in the company, valued at $2,239,880.34. This trade represents a 11.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,136 shares of company stock valued at $4,352,029 over the last ninety days. Company insiders own 14.36% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mackenzie Financial Corp increased its stake in Mirum Pharmaceuticals by 425.2% in the fourth quarter. Mackenzie Financial Corp now owns 19,889 shares of the company’s stock valued at $1,565,000 after purchasing an additional 16,102 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter valued at $3,179,000. Zacks Investment Management purchased a new position in shares of Mirum Pharmaceuticals in the 4th quarter valued at $2,401,000. Vestal Point Capital LP purchased a new position in shares of Mirum Pharmaceuticals in the 4th quarter valued at $5,213,000. Finally, Virtus Investment Advisers LLC raised its stake in Mirum Pharmaceuticals by 16.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 10,513 shares of the company’s stock worth $830,000 after acquiring an additional 1,447 shares in the last quarter.

Mirum Pharmaceuticals Trading Down 13.6%

The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. The stock has a market capitalization of $4.82 billion, a PE ratio of -109.06 and a beta of 0.49. The business’s 50-day moving average is $92.67 and its two-hundred day moving average is $78.81.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.